Literature DB >> 21810606

STAT3 negatively regulates type I IFN-mediated antiviral response.

Wei-Bei Wang1, David E Levy, Chien-Kuo Lee.   

Abstract

Type I IFNs are crucial cytokines of innate immunity for combating viral infections. Signaling through type I IFN receptors triggers the activation of STAT proteins, including STAT1, STAT2, and STAT3. Although an essential role of STAT1 and STAT2 for type I IFN-induced antiviral response has been well established by studies of gene-targeted mice and human mutations, the role of STAT3 for this response remains unclear. Using gain-of-function and loss-of-function approaches, we demonstrated that STAT3 negatively regulates type I IFN-mediated response. STAT3 knockdown or knockout cells displayed enhanced gene expression and antiviral activity in response to IFN-α/β. Restoration of STAT3 to STAT3KO cells resulted in attenuation of the response. Upon viral infection, increased type I IFN production in STAT3KO cells resulted in enhanced STAT activation and ISG expression. One mechanism for the enhanced IFN production and response in the absence of STAT3 might operate through an MDA5-dependent manner. STAT3 also appeared to suppress IFN response directly in a manner dependent on its N-terminal domain and independent of its function as a transcriptional factor. Taken together, these results define STAT3 as a negative regulator of type I IFN response and provide a therapeutic target for viral infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21810606     DOI: 10.4049/jimmunol.1004128

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  90 in total

Review 1.  The immunology of influenza virus-associated bacterial pneumonia.

Authors:  Keven M Robinson; Jay K Kolls; John F Alcorn
Journal:  Curr Opin Immunol       Date:  2015-02-24       Impact factor: 7.486

2.  Investigation of JAKs/STAT-3 in lipopolysaccharide-induced intestinal epithelial cells.

Authors:  L Fu; L-W Wei; M-D Zhao; J-L Zhu; S-Y Chen; X-B Jia; S-J Lai
Journal:  Clin Exp Immunol       Date:  2016-08-01       Impact factor: 4.330

3.  Type I IFN augments IL-27-dependent TRIM25 expression to inhibit HBV replication.

Authors:  Guangyun Tan; Qingfei Xiao; Hongxiao Song; Feng Ma; Fengchao Xu; Di Peng; Na Li; Xiaosong Wang; Junqi Niu; Pujun Gao; F Xiao-Feng Qin; Genhong Cheng
Journal:  Cell Mol Immunol       Date:  2017-02-13       Impact factor: 11.530

4.  STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.

Authors:  S Marozin; J Altomonte; K A Muñoz-Álvarez; A Rizzani; E N De Toni; W E Thasler; R M Schmid; O Ebert
Journal:  Cancer Gene Ther       Date:  2015-05-01       Impact factor: 5.987

5.  Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity.

Authors:  Tiancen Hu; Jennifer E Yeh; Luca Pinello; Jaison Jacob; Srinivas Chakravarthy; Guo-Cheng Yuan; Rajiv Chopra; David A Frank
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

Review 6.  Type I interferon signaling, regulation and gene stimulation in chronic virus infection.

Authors:  Sabelo Lukhele; Giselle M Boukhaled; David G Brooks
Journal:  Semin Immunol       Date:  2019-05-30       Impact factor: 11.130

7.  Genetic Analyses of Contributions of Viral Interleukin-6 Interactions and Signaling to Human Herpesvirus 8 Productive Replication.

Authors:  Qian Li; Qiwang Xiang; Daming Chen; John Nicholas
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

8.  Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance.

Authors:  Robert Kuo; Eiji Saito; Stephen D Miller; Lonnie D Shea
Journal:  Mol Ther       Date:  2017-04-10       Impact factor: 11.454

Review 9.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

10.  Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.

Authors:  Kuo-Sheng Hsu; Xuan Zhao; Xiwen Cheng; Dongyin Guan; Ganapati H Mahabeleshwar; Yu Liu; Ernest Borden; Mukesh K Jain; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.